Antiviral Strategies for Pandemic and Seasonal Influenza

doi:10.3390/v2081766

This article is

freely available
re-usable

Viruses 2010, 2(8), 1766-1781; doi:10.3390/v2081766

Review

Antiviral Strategies for Pandemic and Seasonal Influenza

Maria Hedlund, Jeffrey L. Larson and Fang Fang*

NexBio, Inc./10665 Sorrento Valley Rd, San Diego, CA 92121, USA

* Author to whom correspondence should be addressed.

Received: 11 June 2010; in revised form: 6 August 2010 / Accepted: 11 August 2010 / Published: 20 August 2010

(This article belongs to the Special Issue Antivirals Against Influenza)

Download PDF Full-Text [259 KB, uploaded 20 August 2010 17:34 CEST]

Abstract: While vaccines are the primary public health response to seasonal and pandemic flu, short of a universal vaccine there are inherent limitations to this approach. Antiviral drugs provide valuable alternative options for treatment and prophylaxis of influenza. Here, we will review drugs and drug candidates against influenza with an emphasis on the recent progress of a host-targeting entry-blocker drug candidate, DAS181, a sialidase fusion protein.

Keywords: influenza virus; neuraminidase inhibitors; sialic acid; RNA polymerase

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Hedlund, M.; Larson, J.L.; Fang, F. Antiviral Strategies for Pandemic and Seasonal Influenza. Viruses 2010, 2, 1766-1781.

AMA Style

Hedlund M, Larson JL, Fang F. Antiviral Strategies for Pandemic and Seasonal Influenza. Viruses. 2010; 2(8):1766-1781.

Chicago/Turabian Style

Hedlund, Maria; Larson, Jeffrey L.; Fang, Fang. 2010. "Antiviral Strategies for Pandemic and Seasonal Influenza." Viruses 2, no. 8: 1766-1781.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert